© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BrainsWay Ltd. (BWAY) stock declined over -0.69%, trading at $14.30 on NASDAQ, down from the previous close of $14.40. The stock opened at $14.55, fluctuating between $14.09 and $14.67 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | 14.55 | 14.67 | 14.09 | 14.30 | 53.37K |
| Aug 27, 2026 | 14.61 | 14.61 | 14.15 | 14.40 | 96.56K |
| Aug 26, 2026 | 14.43 | 14.59 | 14.02 | 14.30 | 74.21K |
| Aug 25, 2026 | 14.32 | 14.62 | 14.22 | 14.43 | 56.59K |
| Aug 24, 2026 | 14.53 | 14.53 | 14.10 | 14.19 | 97.71K |
| Aug 21, 2026 | 14.85 | 15.16 | 14.68 | 14.74 | 47.34K |
| Aug 20, 2026 | 15.16 | 15.33 | 14.84 | 14.97 | 53.69K |
| Aug 19, 2026 | 14.88 | 15.20 | 14.88 | 15.17 | 71.27K |
| Aug 18, 2026 | 15.35 | 15.35 | 14.52 | 14.66 | 113.12K |
| Aug 17, 2026 | 16.10 | 16.15 | 15.24 | 15.49 | 186.74K |
| Aug 14, 2026 | 16.27 | 16.66 | 15.89 | 16.32 | 120.96K |
| Aug 13, 2026 | 16.67 | 17.29 | 16.32 | 16.47 | 230.13K |
| Aug 12, 2026 | 15.82 | 17.40 | 14.81 | 16.60 | 622.7K |
| Aug 11, 2026 | 15.18 | 15.27 | 14.86 | 14.98 | 119.31K |
| Aug 10, 2026 | 15.28 | 15.47 | 15.26 | 15.32 | 55.21K |
| Aug 07, 2026 | 15.60 | 16.04 | 15.37 | 15.50 | 86.68K |
| Aug 06, 2026 | 15.52 | 16.50 | 15.48 | 15.65 | 120.55K |
| Aug 05, 2026 | 15.77 | 15.77 | 14.96 | 15.01 | 83.59K |
| Aug 04, 2026 | 15.84 | 16.15 | 15.37 | 15.80 | 140.94K |
| Aug 03, 2026 | 15.34 | 15.86 | 15.29 | 15.81 | 86.59K |
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
| Employees | 129 |
| Beta | 0.15 |
| Sales or Revenue | $31.79M |
| 5Y Sales Change% | -0.027% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Specialties |